Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c ...

The latest trend in health and fitness tracking may sound familiar: wearing continuous glucose monitors (CGMs). Many people ...

As the U.S. stock market navigates a period of mixed performance, with major indices like the Dow Jones and S&P 500 experiencing fluctuations amid economic uncertainties and tariff concerns, investors ...

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

Shares of DexCom Inc. rallied 3.79% to $73.38 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 1.08% to 5,675.29 and the Dow ...

Leo Cullen’s team are about to road test their unbeaten record in all competitions – including 12 straight wins in the URC – ...

Tandem Diabetes Care (Nasdaq:TNDM) today announced positive data supporting its automated insulin delivery technology for ...

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...